{
"METABOLOMICS WORKBENCH":{"STUDY_ID":"ST003030","ANALYSIS_ID":"AN004967","VERSION":"1","CREATED_ON":"01-11-2024"},

"PROJECT":{"PROJECT_TITLE":"A small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation","PROJECT_SUMMARY":"Macrophage migration inhibitory factor (MIF) is an innate cytokine that regulates both inflammatory and homeostatic responses. MIF is expressed by cardiomyocytes, where it exerts a protective action against ischemia-reperfusion (I/R) injury by activating AMP-activated protein kinase (AMPK). This effect is attenuated in the senescent heart due to an intrinsic, age-related reduction in MIF expression. We hypothesized that treating the aged heart with the small molecule MIF agonist (MIF20) can reinforce protective MIF signaling in cardiomyocytes, leading to a beneficial effect against I/R stress. The administration of MIF20 at the onset of reperfusion was found to not only decrease myocardial infarct size but also preserves systolic function in the aged heart. Protection from I/R injury was reduced in mice with cardiomyocyte-specific Mif deletion, consistent with the mechanism of action of MIF20 to allosterically increase MIF affinity for its cognate receptor CD74. We further found MIF20 to contribute to the maintenance of mitochondrial fitness and to preserve the contractile properties of aged cardiomyocytes under hypoxia/reoxygenation. MIF20 augments protective metabolic responses by reducing the NADH/NAD ratio, leading to a decrease in the accumulation of reactive oxygen species (ROS) in the aged myocardium under I/R stress. We also identify alterations in the expression levels of the downstream effectors PDK4 and LCAD, which participate in the remodeling of the cardiac metabolic profile. Data from this study demonstrates that pharmacologic augmentation of MIF signaling provides beneficial homeostatic actions on senescent myocardium under I/R stress.","INSTITUTE":"University of Mississippi Medical Center","LAST_NAME":"Li","FIRST_NAME":"Ji","ADDRESS":"2500 N State St, Jackson, MS 39216-4505","EMAIL":"jli3@umc.edu","PHONE":"6018158995","DOI":"http://dx.doi.org/10.21228/M89X4H"},

"STUDY":{"STUDY_TITLE":"A small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation - Part 2","STUDY_SUMMARY":"Macrophage migration inhibitory factor (MIF) is an innate cytokine that regulates both inflammatory and homeostatic responses. MIF is expressed by cardiomyocytes, where it exerts a protective action against ischemia-reperfusion (I/R) injury by activating AMP-activated protein kinase (AMPK). This effect is attenuated in the senescent heart due to an intrinsic, age-related reduction in MIF expression. We hypothesized that treating the aged heart with the small molecule MIF agonist (MIF20) can reinforce protective MIF signaling in cardiomyocytes, leading to a beneficial effect against I/R stress. The administration of MIF20 at the onset of reperfusion was found to not only decrease myocardial infarct size but also preserves systolic function in the aged heart. Protection from I/R injury was reduced in mice with cardiomyocyte-specific Mif deletion, consistent with the mechanism of action of MIF20 to allosterically increase MIF affinity for its cognate receptor CD74. We further found MIF20 to contribute to the maintenance of mitochondrial fitness and to preserve the contractile properties of aged cardiomyocytes under hypoxia/reoxygenation. MIF20 augments protective metabolic responses by reducing the NADH/NAD ratio, leading to a decrease in the accumulation of reactive oxygen species (ROS) in the aged myocardium under I/R stress. We also identify alterations in the expression levels of the downstream effectors PDK4 and LCAD, which participate in the remodeling of the cardiac metabolic profile. Data from this study demonstrates that pharmacologic augmentation of MIF signaling provides beneficial homeostatic actions on senescent myocardium under I/R stress.","INSTITUTE":"University of Mississippi Medical Center","LAST_NAME":"Li","FIRST_NAME":"Ji","ADDRESS":"2500 N State St, Jackson, MS 39216-4505","EMAIL":"jli3@umc.edu","PHONE":"6018158995","SUBMIT_DATE":"2023-12-18"},

"SUBJECT":{"SUBJECT_TYPE":"Mammal","SUBJECT_SPECIES":"Mus musculus","TAXONOMY_ID":"10090"},
"SUBJECT_SAMPLE_FACTORS":[
{
"Subject ID":"-",
"Sample ID":"7_19",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R"},
"Additional sample data":{"Weight":"78"}
},
{
"Subject ID":"-",
"Sample ID":"7_20",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R"},
"Additional sample data":{"Weight":"46"}
},
{
"Subject ID":"-",
"Sample ID":"7_21",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R"},
"Additional sample data":{"Weight":"68"}
},
{
"Subject ID":"-",
"Sample ID":"8_22",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R +MIF20"},
"Additional sample data":{"Weight":"73"}
},
{
"Subject ID":"-",
"Sample ID":"8_23",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R +MIF20"},
"Additional sample data":{"Weight":"62"}
},
{
"Subject ID":"-",
"Sample ID":"8_24",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Aged I/R +MIF20"},
"Additional sample data":{"Weight":"78"}
},
{
"Subject ID":"-",
"Sample ID":"5_13",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged"},
"Additional sample data":{"Weight":"80"}
},
{
"Subject ID":"-",
"Sample ID":"5_14",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged"},
"Additional sample data":{"Weight":"64"}
},
{
"Subject ID":"-",
"Sample ID":"5_15",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged"},
"Additional sample data":{"Weight":"58"}
},
{
"Subject ID":"-",
"Sample ID":"6_16",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged+MIF20"},
"Additional sample data":{"Weight":"54"}
},
{
"Subject ID":"-",
"Sample ID":"6_17",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged+MIF20"},
"Additional sample data":{"Weight":"65"}
},
{
"Subject ID":"-",
"Sample ID":"6_18",
"Factors":{"Genotype":"Aged-wildtype","Treatment":"Sham aged+MIF20"},
"Additional sample data":{"Weight":"79"}
},
{
"Subject ID":"-",
"Sample ID":"1_1",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young"},
"Additional sample data":{"Weight":"77"}
},
{
"Subject ID":"-",
"Sample ID":"1_2",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young"},
"Additional sample data":{"Weight":"66"}
},
{
"Subject ID":"-",
"Sample ID":"1_3",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young"},
"Additional sample data":{"Weight":"80"}
},
{
"Subject ID":"-",
"Sample ID":"2_4",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young+MIF20"},
"Additional sample data":{"Weight":"72"}
},
{
"Subject ID":"-",
"Sample ID":"2_5",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young+MIF20"},
"Additional sample data":{"Weight":"45"}
},
{
"Subject ID":"-",
"Sample ID":"2_6",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Sham young+MIF20"},
"Additional sample data":{"Weight":"60"}
},
{
"Subject ID":"-",
"Sample ID":"3_7",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R"},
"Additional sample data":{"Weight":"71"}
},
{
"Subject ID":"-",
"Sample ID":"3_8",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R"},
"Additional sample data":{"Weight":"65"}
},
{
"Subject ID":"-",
"Sample ID":"3_9",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R"},
"Additional sample data":{"Weight":"80"}
},
{
"Subject ID":"-",
"Sample ID":"4_10",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R+MIF20"},
"Additional sample data":{"Weight":"80"}
},
{
"Subject ID":"-",
"Sample ID":"4_11",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R+MIF20"},
"Additional sample data":{"Weight":"66"}
},
{
"Subject ID":"-",
"Sample ID":"4_12",
"Factors":{"Genotype":"Young-wildtype","Treatment":"Young I/R+MIF20"},
"Additional sample data":{"Weight":"57"}
}
],
"COLLECTION":{"COLLECTION_SUMMARY":"The sample collection method was as follows: All mouse groups underwent anesthesia with 2%-3% isoflurane and 100% O2. The mouse hearts were excised and rinsed in ice-cold PBS. Both atriums were removed; only the left ventricular myocardium, including the infarct area, was collected and was quickly frozen by using liquid nitrogen. Samples were preserved below -80 °C and were sent out for metabolomic analysis.","SAMPLE_TYPE":"Heart"},

"TREATMENT":{"TREATMENT_SUMMARY":"Sham young;Sham young+MIF20;Young I/R;Young I/R+MIF20;Sham aged;Sham aged+MIF20;Aged I/R;Aged I/R +MIF20"},

"SAMPLEPREP":{"SAMPLEPREP_SUMMARY":"The metabolomic sample preparation method was: The tissue samples were ground into a homogenous powder with a Retsch Cryomill (Retsch-Allee, Haan, Germany). 45 – 80 mg of the pulverized sample was weighed and stored in the -80 oC freezer prior to extraction. Samples were allowed to thaw at 4 °C for 30 min before adding 1.5 mL of 20:40:40 water/methanol/acetonitrile with 0.1 M formic acid for metabolites extraction. The samples were vortexed and centrifuged and the supernatants were isolated and dried completely under nitrogen. The dried samples were resuspended in 300 µL water and an aliquot were transferred to autosampler vials for UHPLC-HRMS analysis. Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA)."},

"CHROMATOGRAPHY":{"CHROMATOGRAPHY_SUMMARY":"Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Metabolites were separated using a Synergi Hydro RP column (2.5 μm, 100 × 2.0 mm; Phenomenex, Torrance, CA, USA) using a reversed phase ion pairing chromatographic method. This method uses a tributylamine ion pairing reagent with a water: methanol solvent gradient elution within a 25-minute duration as reported previously (Bazurto et al, 2018: Bazurto JV, Dearth SP, Tague ED, Campagna SR, Downs DM. Untargeted metabolomics confirms and extends the understanding of the impact of aminoimidazole carboxamide ribotide (AICAR) in the metabolic network of Salmonella enterica. Microb Cell. 2017 Nov 22;5(2):74-87. doi: 10.15698/mic2018.02.613. PMID: 29417056; PMCID: PMC5798407.).","INSTRUMENT_NAME":"Thermo Dionex Ultimate 3000","COLUMN_NAME":"Phenomenex Synergi Hydro-RP (100 x 2mm,2.5um)","COLUMN_TEMPERATURE":"25","FLOW_GRADIENT":"0 to 5 min 0% B, from 5 to 13 min 20% B, from 13 to 15.5 min 55% B, from 15.5 to 19 min 95% B, and from 19 to 25 min 0% B","FLOW_RATE":"200 µL/min","SOLVENT_A":"97:3 LCMS grade water : methanol, 11 mM tributylamine, 15 mM acetic acid.","SOLVENT_B":"LCMS grade methanol","CHROMATOGRAPHY_TYPE":"Reversed phase"},

"ANALYSIS":{"LABORATORY_NAME":"Biological Small Molecule Mass Spectrometry Core, Univ of Tenn, Knoxville","ANALYSIS_TYPE":"MS"},

"MS":{"INSTRUMENT_NAME":"Thermo Exactive Plus Orbitrap","INSTRUMENT_TYPE":"Orbitrap","MS_TYPE":"ESI","MS_COMMENTS":"Mass analysis was carried out at the University of Tennessee Biological and Small Molecule Mass Spectrometry Core (RRID: SCR_021368) using an UltiMate 3000 liquid chromatography system (Dionex, Sunnyvale, CA, USA) coupled to an Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Metabolites were separated using a Synergi Hydro RP column (2.5 μm, 100 × 2.0 mm; Phenomenex, Torrance, CA, USA) using a reversed phase ion pairing chromatographic method. This method uses a tributylamine ion pairing reagent with a water: methanol solvent gradient elution within a 25-minute duration as reported previously (Bazurto et al., 2018). All solvents used were LC-MS grade. The chromatographic gradient was from 0 to 5 min 0% B, from 5 to 13 min 20% B, from 13 to 15.5 min 55% B, from 15.5 to 19 min 95% B, and from 19 to 25 min 0% B. (ref to paper: (Bazurto et al, 2018)) The separated metabolites were ionized using electrospray ionization with negative polarity and the full scan mass analysis was performed with a resolution of 140,000 as previously reported. The Xcalibur (RAW) files generated from the UPLC-HRMS analysis were converted to the mzML format using the msconvert software to enable data centroiding. Metabolomic Analysis and Visualization Engine (MAVEN) was used to integrate the peak areas from the extracted ion chromatograms (EIC). Prior to identification and integration, MAVEN was used to perform a nonlinear retention time correction across all samples. Metabolites were identified by comparing chromatographic retention time and exact masses within ± 5 ppm mass tolerance to an in-house standard library. Identifications were validated using the natural abundance of isotopes in the compound. The integrated peak areas were used for further statistical and biological analysis. Unidentified spectral features were annotated and analyzed using online LC-MS raw data spectra processing features in MetaboAnalyst 5.0.","ION_MODE":"NEGATIVE","MS_RESULTS_FILE":"ST003030_AN004967_Results.txt UNITS:Peak area Has m/z:Yes Has RT:Yes RT units:Seconds"}

}